| http://www.w3.org/ns/prov#value | - Targeting a commonpathway that modulates NLRP3 inflammasome activation could be an attractive newtreatment strategy in diseases in which increased inflammasome activation has beenimplicated, including metabolic diseases such as gout and diabetes.Is There a Role for Tissue-Specific Interleukin-1 Production????The vast majorityof in vitro evaluations of the triggers and responses of inflammasome act
|
